Company Overview and News
The Hong Kong stock market closed higher, with a tepid turnover, after a choppy session on Thursday, as optimism that the US Federal Reserve was unlikely to accelerate the pace of interest rate increases was offset by comments made by US President Donald Trump, which suggested a setback in the US-China trade talks.
WeChat, China’s most popular smartphone app with more than 1 billion active users, now enables residents in southern China’s Guangdong province to skip the queues at government offices and face-to-face talks with civil servants.
As yields and returns in traditional real estate get squeezed, investors are looking at alternative asset classes
The deal is one of several by major vendors such as HPE as they seek to bolster their SDN offerings to enterprises making the transition to the cloud.
Quarterly Revenue jumped 87% over the same period in 2017 Overall Gross Margin Improvement Conference Call on Wednesday May 16, 2018 at 9am ET
China Tower, the world’s biggest operator of mobile phone towers, has applied to list its shares in Hong Kong in what could become the city’s second US$10 billion offering this year.
Good day, and welcome to the Eutelsat Communications Third Quarter 2017-'18 Revenues Conference Call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Rodolphe Belmer. Please go ahead, sir.
BEIJING, May 01, 2018 (GLOBE NEWSWIRE) -- ChinaCache International Holdings Ltd. ("ChinaCache" or the "Company") (NasdaqGS:CCIH), a leading total solutions provider of Internet content and application delivery services in China, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2017 with the Securities and Exchange Commission (the "SEC") on April 30, 2018.
Many large technology companies – including Tencent, Alibaba, Foxconn and Apple – have shown strong support for Beijing’s goal to turn Guizhou province into a world-class hi-tech location
BEIJING, April 27, 2018 (GLOBE NEWSWIRE) -- ChinaCache International Holdings Ltd. ("ChinaCache" or the "Company") (Nasdaq:CCIH), a leading total solutions provider of Internet content and application delivery services in China, today announced that it has terminated the definitive agreement (the “Agreement”) disclosed on March 6, 2017, to sell 79% of the Company’s equity interest in ChinaCache Xin Run Technology (Beijing) Co.
BEIJING, April 26, 2018 (GLOBE NEWSWIRE) -- ChinaCache International Holdings Ltd. ("ChinaCache" or the "Company") (Nasdaq:CCIH) today announced the appointment of Guangsheng Meng as Chief Financial Officer, effective April 20, 2018. Mr. Meng will lead the financial operations of ChinaCache, including Tax, Treasury, Accounting, Internal Audit, Legal and Investor Relations and report directly to Mr.
Nokia (NOK) is breaking out higher from beaten down levels as management looks to improve its fundamental operations. Its share price has trended lower over the last decade, but is showing signs of a reversal higher. This is largely due to management's investment in 5G technologies, aiming to capture market share early in the process. Should management's bets prove correct, the company could see growth in both its top- and bottom-line operations.
HONG KONG, April 23, 2018 (GLOBE NEWSWIRE) -- Finger Motion Inc. (OTC Markets:FNGR) (“Finger Motion” or “The Company”) is pleased to announce two significant business development wins.
Most Americans who think of 5G providers will tend to think of AT&T Inc. (NYSE:T), Verizon Communications Inc. (NYSE:VZ), T-Mobile US Inc (NASDAQ:TMUS), and Sprint Corp (NYSE:S). These providers will provide most of the 5G service to American customers.
Negativity on Wall Street looked set to flow through to Asian markets on Friday, with futures pointing to slightly lower starts for Japan and Australia.
13h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
13h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...